144 related articles for article (PubMed ID: 16874752)
1. Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure.
Fox SH; Lang AE; Brotchie JM
Mov Disord; 2006 Oct; 21(10):1578-94. PubMed ID: 16874752
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Visanji NP; Gomez-Ramirez J; Johnston TH; Pires D; Voon V; Brotchie JM; Fox SH
Mov Disord; 2006 Nov; 21(11):1879-91. PubMed ID: 16960862
[TBL] [Abstract][Full Text] [Related]
3. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Fox SH; Henry B; Hill M; Crossman A; Brotchie J
Mov Disord; 2002 Nov; 17(6):1180-7. PubMed ID: 12465055
[TBL] [Abstract][Full Text] [Related]
5. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
[TBL] [Abstract][Full Text] [Related]
6. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Hill MP; Ravenscroft P; Bezard E; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
J Pharmacol Exp Ther; 2004 Jul; 310(1):386-94. PubMed ID: 15004218
[TBL] [Abstract][Full Text] [Related]
7. Noradrenergic drugs for levodopa-induced dyskinesia.
Colosimo C; Craus A
Clin Neuropharmacol; 2003; 26(6):299-305. PubMed ID: 14646609
[TBL] [Abstract][Full Text] [Related]
8. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
9. Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Ko WK; Pioli E; Li Q; McGuire S; Dufour A; Sherer TB; Bezard E; Facheris MF
Mov Disord; 2014 May; 29(6):772-9. PubMed ID: 24610195
[TBL] [Abstract][Full Text] [Related]
10. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate.
Silverdale MA; Kobylecki C; Hallett PJ; Li Q; Dunah AW; Ravenscroft P; Bezard E; Brotchie JM
Synapse; 2010 Feb; 64(2):177-80. PubMed ID: 19852073
[No Abstract] [Full Text] [Related]
11. Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us?
Bédard PJ; Mancilla BG; Blanchette P; Gagnon C; Di Paolo T
Can J Neurol Sci; 1992 Feb; 19(1 Suppl):134-7. PubMed ID: 1571858
[TBL] [Abstract][Full Text] [Related]
12. Nondopaminergic mechanisms in levodopa-induced dyskinesia.
Brotchie JM
Mov Disord; 2005 Aug; 20(8):919-31. PubMed ID: 16007614
[TBL] [Abstract][Full Text] [Related]
13. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.
Dekundy A; Lundblad M; Danysz W; Cenci MA
Behav Brain Res; 2007 Apr; 179(1):76-89. PubMed ID: 17306893
[TBL] [Abstract][Full Text] [Related]
14. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
Jenner P
Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676
[TBL] [Abstract][Full Text] [Related]
15. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
Iravani MM; Tayarani-Binazir K; Chu WB; Jackson MJ; Jenner P
J Pharmacol Exp Ther; 2006 Dec; 319(3):1225-34. PubMed ID: 16959959
[TBL] [Abstract][Full Text] [Related]
16. Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Aubert I; Guigoni C; Li Q; Dovero S; Bioulac BH; Gross CE; Crossman AR; Bloch B; Bezard E
Biol Psychiatry; 2007 Apr; 61(7):836-44. PubMed ID: 16950226
[TBL] [Abstract][Full Text] [Related]
17. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
[TBL] [Abstract][Full Text] [Related]
18. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
[TBL] [Abstract][Full Text] [Related]
19. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations.
Hauser RA; Shulman LM; Trugman JM; Roberts JW; Mori A; Ballerini R; Sussman NM;
Mov Disord; 2008 Nov; 23(15):2177-85. PubMed ID: 18831530
[TBL] [Abstract][Full Text] [Related]
20. A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale.
Fox SH; Johnston TH; Li Q; Brotchie J; Bezard E
Mov Disord; 2012 Sep; 27(11):1373-8. PubMed ID: 22976821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
